Loading...
Market
Will FILSPARI achieve $500 million in sales by the end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Sales data reported by Travere Therapeutics in their financial statements or press releases
Story
FDA Grants Full Approval to Travere Therapeutics' FILSPARI for IgA Nephropathy, Stock Rises 5.7%
Sep 6, 2024, 01:22 PM
The FDA has granted full approval to Travere Therapeutics' drug FILSPARI (sparsentan), marking it as the only non-immunosuppressive treatment that significantly slows kidney function decline in patients with IgA nephropathy (IgAN). This approval follows a conversion from an accelerated approval and comes with an expanded label. The decision has positively impacted Travere's stock, which saw a 5.7% increase in pre-market trading. The approval is expected to intensify competition with Novartis and Calliditas in the kidney disease treatment market. Ligand Partner is also associated with this approval.
View original story
Similar markets
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
